Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Reexamination Certificate
2001-08-31
2002-11-19
Azpuru, Carlos (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
C424S078030, C424S439000
Reexamination Certificate
active
06482421
ABSTRACT:
Novel pharmaceuticals. dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain.
FIELD OF THE INVENTION
The present invention relates to mixtures comprising at least one of the fatty acids eicosapentaenoic acid (20:5n3) and docosahexaenoic acid (22.6n3) and the plant
Zingiber officinale
Roscoe or parts thereof or an extract or a component thereof.
More specifically, the invention relates to novel pharmaceuticals, dietary supplements or cosmetic compositions containing such mixtures, and to the use of such mixtures for preparing a medicament or a dietary supplement for the suppression of hypersensitivity and/or inflammatory reaction.
BACKGROUND OF THE INVENTION
Hypersensitivity is defined as a state of altered reactivity in which the body reacts with an exaggerated immune response to a substance (antigen). Hypersensitivity may be caused by exogenous or endogenous antigens.
Hypersensitivity reactions underlie a large number of diseases. Among these, allergic and autoimmune conditions are of great importance. A classification of hypersensitivity diseases is given in the textbook Clinical Medicine (Kumar, P. and Clark, M.: “Clinical Medicine”, 3rd edition, p. 147-150, 1994, Bailliere Tindall, London).
Type I hypersensitivity reactions (IgE mediated allergic reactions) are caused by allergens (specific exogenous antigens), e.g. pollen, house dust, animal dandruff, moulds, etc. Allergic diseases in which type I reactions play a significant role include asthma, eczema (atopic dermatitis), urticaria, allergic rhinitis and anaphylaxis.
Type II hypersensitivity reactions are caused by cell surface or tissue bound antibodies (IgG and IgM) and play a significant role in the pathogenesis of myasthenia gravis, Good-pasture's syndrome and Addisonian pernicious anaemia.
Type III hypersensitivity reactions (immune complex) are caused by autoantigens or exogenous antigens, such as certain bacteria, fungi and parasite. Diseases in which type III hypersensitivity reactions play a significant role include lupus erythematosus, rheumatoid arthritis and glomerulonephritis.
Type IV hypersensitivity reactions (delayed) are caused by cell or tissue bound antigens. This type of hypersensitivity plays a significant role in a number of conditions, e.g. graft-versus-host disease, leprosy, contact dermatitis and reactions due to insect bites.
A number of drug classes are available for the treatment of hypersensitivity reactions. Some of these are applied systemically and some are applied topically.
The corticosteroids are among the most widely used drugs for the treatment of hyper-sensitivity diseases. Corticosteroids primarily exert their pharmacological action by non-selectively inhibiting the function and proliferation of different classes of immune cells resulting in suppression of hyper-sensitivity reactions. Unfortunately the corticosteroids are associated with a number of serious side effects, e.g. immuno-suppression, osteoporosis and skin atrophy (when applied topically)
Zingiber officinale
Roscoe (family Zingiberacea), commonly known as ginger, is an erect perennial herb with thick tuberous rhizomes (underground stems) from which the aerial stem grows about 1 m high.
Zingiber officinale
Roscoe is native to Southern Asia ,and is extensively cultivated in the tropics, e.g. India, China, Jamaica, Haiti and Nigeria.
Ginger or ginger volatile oil is widely used as a flavour ingredient in the food industry.
Due to the extensive use of
Zingiber officinale
Roscoe in the food industry, it has been subject to some chemical investigations.
The ginger rhizome contains a volatile oil which can be obtained by steam distillation. The chemical composition of ginger oil depends on its geographic origin. Ginger volatile oil generally contains the sesquiterpenes zingiberene and bisabolene as its major components. Other sesquiterpenes and sesquiterpene alcohols present include ar-curcumene, &bgr;-sesquiphelandrene, sesquithujene, &bgr;-bisabolone, (E)-&agr;-farnesene, zingiberol, zingiberenol, cis-sesquisabinene hydrate, and cis- and trans-sesquiphellandrol. It also contains monoterpenes such as camphor, &bgr;-phellandrene, geranial, neral, linalool, camphene and d-borneol.
Zingiber officinale
Roscoe contains a number of phenolic compounds, most of which have a characteristic hydroxy-methoxy-phenyl moiety. These compounds are responsible for the pungency of ginger. The quantitatively dominating group of these phenolic compounds are the gingerols. The gingerols form a homologous series, 2-gingerol, 4-gingerol, 6-gingerol, 8-gingerol, 10-gingerol, 12-gingerol and 14-gingerol. The quantitatively dominating of these is 6-gingerol. Another group are the shogaols which are dehydration products of gingerols. The shogaols form a similar homologous series. Other similar compounds present are zingerone, 6-gingerdiol, gingerdione, gingerenones A-C, isogingerenone B, etc.
Zingiber officinale
Roscoe has been used in the traditional medicine in China and in the Indian subcontinent for more than 2500 years. The Chinese prescribe fresh or dried ginger for the relief of a number of conditions, e.g. gastrointestinal disturbances, colds, inflammations, headaches and as an antiemetic for the prevention of seasickness.
The traditional use of
Zingiber officinale
Roscoe is limited to consumption of the ginger rhizome in a fresh or dried state. Obtaining an effect based on the traditional use requires high doses of the rhizome (Srivastava K C et al., Med. Hypotheses. May; 29, 1989 (1): 25-8 and Shrivastava K C et al, Med. Hypothesis Dec.; 39, 1992 (4): 342-8).
An inhibiting effect on the formation of pro-inflammatory eicosanoids has been established in vitro for some components of
Zingiber officinale
Roscoe (Kiuchi F, et al, Chem. Pharm. Bull. Tokyo. 1992 Feb; 40(2): 387-91). Furthermore an inhibiting effect of ginger oil on adjuvant arthritis in the rat has been established in vivo (Sharma J N et al, Pharmacology 1994;49: 314-18). Despite these findings, the pharmacological effects of
Zingiber officinale
Roscoe upon administration to humans are mild and only of limited clinical relevance.
The arachidonic acid (AA) metabolism plays an essential role in hyper-sensitivity reactions because AA is converted by the enzyme cyclooxygenase into pro-inflammatory prostaglandins and by the enzyme 5-lipoxygenase into proinflammatory leukotrienes. The prostaglandins and leukotrienes are commonly termed eicosanoids. The modulation of the AA metabolism is a well established pharmacological strategy in relation to the treatment of hyper-sensitivity reactions.
Marine oils, especially fish oils, contain relatively high concentrations of the fatty acids eicosapentaenoic acid (20:5n3) and docosahexaenoic acid (22:6n3). These fatty acids have been shown to reduce inflammatory reactions because they can replace AA in the AA metabolism. The eicosanoids formed by the metabolism of eicosapentaenoic acid (20:5n3) and docosahexaenoic acid (22:6n3) have insignificant pro-inflammatory effects or even antiinflammatory effects.
The drawback in relation to the therapeutic use of eicosapentaenoic acid (20:5n3) and docosahexaenoic acid (22:6n3) is that they are only mildly antiinflammatory and need to be administered for longer periods before a clinical effect can be observed.
SUMMARY OF THE INVENTION
It has been found by the present inventor that a combination of:
a) eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and
b)
Zingiber officinale
Roscoe or parts thereof or an extract or component thereof;
significantly suppresses hyper-sensitivity reactions, and that such a combination is far superior to any of its components when they are used alone.
To the inventor's best knowledge, it is disclosed nowhere in the literature to use a combination of:
a) eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and
b)
Zingiber officinale
Roscoe or parts thereof or an
Azpuru Carlos
Darby & Darby
Eurovita A/S
LandOfFree
PHARMACEUTICALS, DIETARY SUPPLEMENTS AND COSMETIC... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PHARMACEUTICALS, DIETARY SUPPLEMENTS AND COSMETIC..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PHARMACEUTICALS, DIETARY SUPPLEMENTS AND COSMETIC... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2975168